• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Basic studies for an effective therapy for Alport syndrome

Research Project

Project/Area Number 13470159
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypeSingle-year Grants
Section一般
Research Field Pediatrics
Research InstitutionNIIGATA UNIVERSITY

Principal Investigator

UCHIYAMA Makoto  NIIGATA UNIVERSITY Graduate School of Medical and Dental Sciences, Professor, 大学院・医歯学総合研究科, 教授 (80108050)

Co-Investigator(Kenkyū-buntansha) SATOKATA Ichiro  Graduate School of Medical and Dental Sciences, Professor, 大学院・医歯学総合研究科, 教授 (70170800)
Project Period (FY) 2001 – 2002
Project Status Completed (Fiscal Year 2002)
Budget Amount *help
¥8,200,000 (Direct Cost: ¥8,200,000)
Fiscal Year 2002: ¥3,200,000 (Direct Cost: ¥3,200,000)
Fiscal Year 2001: ¥5,000,000 (Direct Cost: ¥5,000,000)
KeywordsAlport syndrome / cyclosporin A / enalapril / tenascin C / Col4a4 / gene therapy / electroporation / trancegenic mouse / サイクロポリンA / ミゾリビン
Research Abstract

1. Study for the efficiency of drug therapy for Alport syndrome using Col4a4 deficient mice
Compared with untreated and mizoribine-treated groups, proteinuria and crescent formation were significantly reduced in cyclosporine A-treated and enalapril-treated groups. Furthermore, enalapril could significantly prolong the survival period of mutant mice, although cyclosporine A and mizoribine could not. Taken together, angiotensin converting enzyme inhibitor was thought to be effective in slowing down the progression towards renal failure in a mouse model of Alport syndrome.
2. Analysis of Col4a4, tenascin double deficient mice
Compared with Col4a4 deficient mice, proteinuria and survival period were significantly improved in Col4a4, tenascin double deficient mice. Elavation of tenascin gene expression observed at the glomerular basement membrane of Col4a4 deficient mice was thought to play a role for promote the pathological change of Alport syndrome.
3. Rescue study of the phenotype of Col4a4 deficient mice by Col4a4 transgenic mice
Col4a4 transgenic mice carrying CAG promoter and LacZ reporter gene were produced. The mice were mated with Col4a4 deficient mice. We are now examining whether the phenotype of Col4a4 deficient mice is rescued or not.
4. Study of gene therapy for Alport syndrome using electroporation
The plasmid pCAG- Col4a4-LacZ was electroporated into mouse kidneys by either abdominal aorta route or renal capsule route. Although efficiency of DNA introduction via abdominal aorta was very low, considerable number of cells in renal cortex were introduced the plasmid by electroporation from subcapsular route. The electroporation from subcapsular route may be available for gene therapy for Alport syndrome and other renal diseases.

Report

(3 results)
  • 2002 Annual Research Report   Final Research Report Summary
  • 2001 Annual Research Report

URL: 

Published: 2001-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi